Nano™ 2nd Gen Pen Needles are the only pen needles aligned to expert recommendations1*.
Company Background
embecta is a global company that develops and provides solutions that make life better for people living with diabetes.
We are the leading producer of insulin injection devices in the world, making about 8 billion injection devices a year, which are used by about 30 million people in more than 100 countries.
Our broad portfolio of products — complemented by education, training, and support resources — helps people with diabetes deliver their insulin correctly.
Product Overview
In April 2025, an updated set of global best practices for insulin injection technique and education was published in Mayo Clinic Proceedings. These recommendations, known as FITTER Forward, highlight the importance of pen needle technology and proper injection technique.
Nano™ 2nd Gen Pen Needles are the only pen needles with a contoured needle base†, and key features that experts recommend.1*
Experts reccommend a 4mm x32G pen needle with these key features1*:
- Contoured needle base
- 5-bevel tip
- Ultra-thin wall technology
NRC#83017-0550-03
A 4mm contoured base pen needle distributes forces across the skin surface, for a more consistent 4mm target injection depth, less bruising, and reduced risk of intramuscular (IM) injection1,2.
Consider dispensing Nano™ 2nd Gen Pen Needles to your patients, to help them have a better injection experience3‡.
More Information
Visit www.embecta.com/en-us/hcp/pen-needles/nano-2nd-gen to learn more about Nano™ 2nd Gen Pen Needles.
Learn more about the FITTER Forward recommendation at www.fitterdiabetes.com.
*A contoured-base pen needle distributes pressure more evenly, reducing the risk of intramuscular injections. While flat-base pen needles are available, currently there is little to no evidence supporting their impact. See reference 1. †Patent information provided upon written request. ‡226 patients with diabetes on insulin treatment were studied with a 150 mm visual analog scale (mean scores of >0 mm; clinically significant difference of ≥5 mm). Nano™ 2nd Gen demonstrated superiority vs. all comparator groups combined for feeling more comfortable throughout injection experience and for overall ease of use. [Comfort (P <0.05) (Mean +18.0 mm, 95% CI, +11.6 to +24.3 mm)]; [Easier (P <0.05)(Mean 19.9 mm, 95% CI, +13.8 to +25.9 mm)].
- Klonoff DC, Berard L, Franco DR, et al. Advance Insulin Injection Technique and Education with FITTER Forward Expert Recommendations. Mayo Clin Proc. 2025; 100(4):682-699. 2. Rini C, Roberts BC, Morel D, et al. Evaluating the impact of human factors and pen needle design on insulin pen injection. J Diabetes Sci Technol. 2019;13(3):533-545.
- Whooley S, Briskin T, Gibney MA, et al. Evaluating the user performance and experience with a re-engineered 4 mm x 32G pen needle: a randomized trial with similar length/gauge needles. Diabetes Ther. 2019;10(2):697-712.
